KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), corresponding to amino acids 11–13 of the 13-residue neuropeptide. Its plasma half-life is estimated at minutes based on tripeptide class pharmacokinetics (MW ~340 Da, no structural modifications)[1]. No published human pharmacokinetic study exists. KPV exerts anti-inflammatory effects via melanocortin receptor 1 (MC1R) activation and NF-κB pathway suppression, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Studied for inflammatory bowel disease, gut epithelial protection, and systemic anti-inflammatory applications. All data is from animal studies or in vitro models — no FDA approval; research use only.
| Parameter | Value | Source |
|---|---|---|
| Plasma Half-Life (systemic, estimated) | ~Minutes (inferred from tripeptide class) | Structural inference [1] |
| Time to Peak (Tmax) | No published data | — |
| Route(s) of Administration | SC injection, Oral (gut research), Topical | — |
| Plasma Protein Binding | No published data | — |
| Full Clearance (5 × t½, estimated) | ~25–75 minutes (estimated) | Calculated from estimate |
| Biological Effect Duration | Hours (NF-κB cascade suppression) | Dalmasso et al. 2008 [1] |
| Standard Research Protocol | 0.5–1 mg SC or oral, once or twice daily | Community protocol |
| Data Quality | Animal/In-vitro — No published human PK study; half-life estimated from peptide class as of May 2026 | — |
KPV's plasma half-life has not been formally established in any published human or animal pharmacokinetic study. KPV (Lys-Pro-Val) is an unmodified tripeptide (MW ~340 Da) — a structural profile that predicts very rapid clearance via circulating serum peptidases (aminopeptidases, dipeptidases) and renal glomerular filtration. Based on these characteristics and analogy to other small unmodified tripeptides, plasma half-life is estimated at minutes.
Dalmasso et al. (2008, PMID 21172242)[1] established KPV's anti-inflammatory mechanism in murine colitis models and in vitro epithelial cell systems, demonstrating that MC1R-mediated NF-κB suppression reduces pro-inflammatory cytokine production and attenuates intestinal inflammation. This paper defines KPV's mechanism of action but does not characterize pharmacokinetic parameters. The anti-inflammatory effects observed — manifesting over hours in cell culture and over days in animal colitis models — are consistent with a short plasma half-life paired with prolonged cascade-driven biological activity.
α-MSH (alpha-melanocyte-stimulating hormone) is a 13-amino-acid neuropeptide produced from pro-opiomelanocortin (POMC) by post-translational processing. The C-terminal tripeptide KPV (amino acids 11–13) retains much of α-MSH's anti-inflammatory potency through MC1R activation. KPV is structurally simpler than the parent peptide — a tripeptide versus a 13-mer — and is expected to clear from plasma at least as rapidly as the parent neuropeptide, if not faster, given its smaller size and greater susceptibility to exopeptidase cleavage[1].
KPV's anti-inflammatory biological effects outlast its estimated plasma half-life through intracellular signaling cascade activation. MC1R is a GPCR; KPV engagement activates downstream cAMP/PKA signaling and NF-κB pathway suppression — an intracellular transcriptional regulatory effect that persists for hours after the initiating ligand has cleared from plasma[1]. This is the same pharmacokinetic/pharmacodynamic dissociation principle seen across signaling peptides: brief receptor engagement triggers a sustained downstream intracellular response.
Based on the estimated plasma half-life of approximately 5–15 minutes, systemic clearance would be expected within approximately 25–75 minutes after injection:
| Half-Lives Elapsed | Time Post-Injection (Estimated) | % Remaining (Theoretical) |
|---|---|---|
| 1 | ~5–15 minutes | 50% |
| 2 | ~10–30 minutes | 25% |
| 3 | ~15–45 minutes | 12.5% |
| 4 | ~20–60 minutes | 6.25% |
| 5 (clearance threshold) | ~25–75 minutes | ~3% |
| Biological effect duration | Hours (NF-κB cascade; animal/in-vitro data) | — |
For subcutaneous injection, KPV reaches peak plasma concentration within approximately 5–15 minutes, then clears within ~75 minutes. Anti-inflammatory effects (NF-κB suppression, cytokine reduction) persist for hours through activated cascade mechanisms. For oral dosing, the target (gut epithelial MC1R) is contacted before systemic absorption, making the clearance timeline primarily relevant for systemic distribution applications[1].
The key insight for understanding KPV's oral research use is that gut anti-inflammatory targets (MC1R on intestinal epithelial cells and immune cells in the lamina propria) are accessible to orally administered KPV before systemic degradation. KPV does not need to survive into plasma to exert gut anti-inflammatory effects — it needs to contact its receptor on the gut mucosal surface. Dalmasso et al. (2008)[1] demonstrated that KPV is taken up via the PepT1 transporter on intestinal epithelial cells, facilitating direct intracellular access. This transporter-mediated uptake mechanism may protect KPV from luminal degradation and deliver intact tripeptide directly into epithelial cells, where it suppresses NF-κB independently of plasma pharmacokinetics.
| Compound | Plasma Half-Life | Data Quality | Primary Anti-inflammatory Mechanism |
|---|---|---|---|
| KPV | ~Minutes (estimated) | Animal/In-vitro | MC1R → NF-κB suppression, cytokine reduction |
| BPC-157 | ~15 min (SC, rat) | Animal Study | VEGFR2, Akt-eNOS (also anti-inflammatory) |
| GHK-Cu | ~0.5–1 hr (estimated) | Animal/In-vitro | TGF-β, MMP modulation, SOD upregulation |
| LL-37 | ~Minutes (estimated) | In-vitro/Animal | TLR4 modulation, immunomodulation |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | ~Minutes (estimated) | No published data | ~5–15 min (estimated) | Systemic distribution; most common research protocol |
| Oral | Local gut — systemic t½ not applicable | Low systemic; high local gut via PepT1 | Local: ~30–60 min | Gut IBD/colitis research; PepT1-mediated epithelial uptake |
| Topical | Local dermal — not systemic | Limited systemic absorption | Local: 1–2 hr (estimated) | Skin anti-inflammatory research |
| Intravenous | No published data | 100% | Minutes | Reference route; not used in research protocols |
KPV is not detected by standard workplace urine drug screens, WADA anti-doping panels, or any broadly deployed drug testing platform. Standard immunoassay drug tests target specific controlled substance classes with no cross-reactivity with tripeptide compounds. GC-MS confirmation panels do not include KPV.
No published forensic detection study has characterized the urinary detection window for KPV. KPV is not on WADA's monitoring program as of May 2026. Given the very short estimated plasma half-life, extremely small molecular weight (~340 Da), and rapid degradation to amino acids (Lys, Pro, Val — all endogenous), detection of intact exogenous KPV in urine would require highly sensitive and specifically targeted LC-MS/MS methodology that has not been published.
KPV's rapid estimated clearance is a direct consequence of its molecular simplicity. As an unmodified tripeptide (Lys-Pro-Val, MW ~340 Da), KPV has no structural defenses against the serum peptidases that degrade small unmodified peptides within minutes of systemic exposure. Lysine at the N-terminus is a preferred substrate for serum aminopeptidases; the resulting Lys cleavage leaves Pro-Val, which is further hydrolyzed by circulating dipeptidases. All three constituent amino acids (Lys, Pro, Val) are endogenous and rapidly re-enter metabolic pools[1].
Despite rapid plasma clearance, KPV's anti-inflammatory mechanism is well established. MC1R is a GPCR that, upon KPV engagement, activates adenylyl cyclase to elevate intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates IκBα, stabilizing it and preventing its proteasomal degradation — thereby retaining NF-κB in the cytoplasm and preventing its nuclear translocation and transcriptional activation. NF-κB drives expression of IL-1β, IL-6, TNF-α, IL-8, and other pro-inflammatory mediators. KPV's suppression of this pathway produces a sustained reduction in pro-inflammatory cytokine production that outlasts the peptide's plasma presence by hours[1].
The additional discovery by Dalmasso et al. (2008)[1] that KPV is a substrate for the PepT1 intestinal oligopeptide transporter is pharmacokinetically significant: PepT1-mediated uptake allows KPV to be transported directly into intestinal epithelial cells intact, bypassing luminal degradation that would otherwise prevent meaningful local concentrations. This transporter-dependent mechanism makes KPV pharmacokinetically unique among signaling tripeptides and provides a mechanistic basis for oral efficacy in gut inflammatory conditions that is independent of systemic plasma pharmacokinetics.
Log injection timing, dose, and route on-device. Free iOS app. No data shared externally.
Download on App StoreThe Halflife app tracks KPV alongside 44 other compounds — all with citation-backed pharmacokinetic data. Free on iOS.
Download on the App Store